Liver/Biliary Disorders News

Asian patients with hepatocellular carcinoma had the lowest waitlist dropout rates and highest 5-year survival after liver transplantation before and after the policy change, while Black or African American patients had the worst outcomes.

BOSTON — Although primary care physicians play a vital role in managing metabolic dysfunction-associated steatotic liver disease, many are not following guidance on screening, risk stratification or referrals, according to research.

BOSTON — Patients with metabolic dysfunction-associated steatotic liver disease who underwent bariatric surgery lost less weight over 5 years than those without MASLD, according to research presented at The Liver Meeting.

Tenofovir disoproxil improved long-term overall and recurrence-free survival rates compared with entecavir among patients with hepatitis B virus-related hepatocellular carcinoma who underwent liver resection.

BOSTON — Women who experience food insecurity and have a BMI less than 25 kg/m2 had higher odds of hepatic steatosis compared with overweight women or those with obesity, regardless of HIV status, according to research at The Liver Meeting.

Nearly twice as many hepatitis A virus-related deaths were reported in the United States from 2016 to 2022 compared with the previous 6 years, with individuals who use drugs or experience homelessness and unstable housing most at risk.

Acamprosate and oral naltrexone were associated with significantly improved alcohol consumption outcomes compared with placebo and could be used alongside psychosocial interventions as first-line treatment for alcohol use disorder.

BOSTON — LPCN 1148, an oral androgen receptor agonist, improved sarcopenia, hepatic encephalopathy and other biomarkers associated with end-stage liver disease among men with advanced cirrhosis and clinical decompensation.

BOSTON — Pegozafermin improved fibrosis and other key noninvasive tests at 24 weeks in patients with metabolic dysfunction-associated steatohepatitis-related cirrhosis, according to data presented at The Liver Meeting.

BOSTON — After 52 weeks, elafibranor achieved biochemical response and improved symptoms of pruritus in patients with primary biliary cholangitis, according to late-breaking data presented at The Liver Meeting.